Brief: Astrazeneca Pharma India Surrenders Marketing Authorisation For Olaparib Tablets
15/04/2025 07:32
April 15 (Reuters) - Astrazeneca Pharma India Ltd ASTR.NS: SURRENDERS MARKETING AUTHORISATION FOR OLAPARIB TABLETS DISCONTINUATION DUE TO COMMERCIAL REASONS, NOT EFFICACY OR SAFETY HOLDS ALL OTHER PERMISSIONS FOR OLAPARIB IN INDIA NEVER MARKETED OLAPARIB INDICATION IN INDIA Source text: ID:nBSE1YlFfg Further company coverage: ASTR.NS ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Astrazeneca Pharma India
See all newsBrief: Astrazeneca Pharma India Receives Permission To Import And Sell Trastuzumab Deruxtecan For Additional Indication
Brief: Astrazeneca Pharma Says Bhavana Agrawal Resigns As CFO
Brief: Astrazeneca Pharma India Receives Permission To Import And Sell Benralizumab For Additional Indication
Brief: Astrazeneca Pharma India Receives Permission To Import Benralizumab (Fasenra) For Additional Indication
Brief: Astrazeneca Pharma Gets Permission To Import For Sale Of Trastuzumab Deruxtecan